Growth factor: Difference between revisions
Jump to navigation
Jump to search
imported>Robert Badgett No edit summary |
imported>Robert Badgett No edit summary |
||
| Line 12: | Line 12: | ||
| [[Endothelial growth factor]]s || || | | [[Endothelial growth factor]]s || || | ||
|- | |- | ||
| [[Epidermal growth factor]] || [[Cetuximab]]<br/>[[Erlotinib]]<br/>[[Gefitinib]]|| Non-small cell [[lung cancer|lung carcinoma]] (NSCLC)<br/> [[Pancreatic cancer]] | | [[Epidermal growth factor]] || [[Cetuximab]]<br/> [[Afatinib]]]<br/>[[Erlotinib]]<br/>[[Gefitinib]]|| Non-small cell [[lung cancer|lung carcinoma]] (NSCLC)<br/> [[Pancreatic cancer]] | ||
|- | |- | ||
| [[Fibroblast growth factor]]s || || | | [[Fibroblast growth factor]]s || || | ||
Revision as of 20:27, 18 September 2013
In biology and medicine, growth factors are intercellular signaling peptides and proteins that are "regulatory proteins and peptides that are signaling molecules involved in the process of paracrine communication. They are generally considered factors that are expressed by one cell and are responded to by receptors on another nearby cell. They are distinguished from hormones in that their actions are local rather than distal."[1]
| Growth factor | Chemotherapeutic agent | Malignancy |
|---|---|---|
| Anaplastic lymphoma kinase | Crizotinib | Anaplastic large-cell lymphoma ALK-positive non-small cell lung carcinoma (NSCLC) |
| Angiogenic proteins | Bevacizumab | Non-small cell lung carcinoma (NSCLC) Breast cancer Colorectal cancer |
| Endothelial growth factors | ||
| Epidermal growth factor | Cetuximab Afatinib] Erlotinib Gefitinib |
Non-small cell lung carcinoma (NSCLC) Pancreatic cancer |
| Fibroblast growth factors | ||
| Nerve growth factor | ||
| Somatomedins | ||
| Tumor necrosis factors | ||
| Vascular endothelial growth factors |
References
- ↑ Anonymous (2024), Growth factor (English). Medical Subject Headings. U.S. National Library of Medicine.